Connect Biopharma Holdings Limited Adjustments For Unrealised Foreign Exchange Losses Gains
Connect Biopharma Holdings Limited (CNTB) reported Adjustments For Unrealised Foreign Exchange Losses Gains of -$61.00 thousand for the 6-month period ending 2024-06-30, per its 6-K filed 2024-09-05.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2024-09-05
CNY
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|
| 2023-06-30 | -3.43M CNY 6-K · filed 2023-09-12 | |
| 2022-12-31 | -9.63M CNY 20-F · filed 2023-04-11 | |
| 2022-06-30 | -7.76M CNY 6-K · filed 2023-09-12 | |
| 2021-12-31 | 3.31M CNY 20-F · filed 2023-04-11 | |
| 2021-06-30 | 741.00K CNY 6-K · filed 2022-09-13 | |
| 2020-12-31 | 6.77M CNY 20-F · filed 2023-04-11 | |
| 2019-12-31 | -1.37M CNY 20-F · filed 2022-03-31 |
USD
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|
| 2024-06-30 | -$61.00K 6-K · filed 2024-09-05 | |
| 2023-12-31 | -$367.00K 20-F · filed 2024-04-16 | |
| 2023-06-30 | -$481.00K 6-K · filed 2024-09-05 | |
| 2022-12-31 | -$1.47M 20-F · filed 2024-04-16 | |
| 2021-12-31 | $516.00K 20-F · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |